Virginia

Global health R&D delivers for Virginia

Click here to select a new state Download PDF

Select a new state

US government investment in global health R&D has delivered

$874.5 million

to Virginia research institutions

9,700+ new jobs

for Virginia

Neglected diseases in Virginia

Chikungunya cases

Dengue cases

129

HIV diagnoses

8673

Malaria cases

484

Tuberculosis cases

2081

West Nile cases

Zika cases

118

Virginia's top USG-funded global health R&D institutions

Department of Defense (self-funding and other agency transfers)

$630.2 million

CONRAD

$145.8 million

Virginia Polytechnic Institute and State University (Virginia Tech)

$32.1 million

American Type Culture Collection

$27.6 million

University of Virginia

$21.5 million

US National Science Foundation

$9.3 million

Eastern Virginia Medical School

$2.6 million

US Civilian Research and Development Foundation (CRDF Global)

$545 thousand

University of Richmond

$500 thousand

James Madison University

$446 thousand

Ferrum College

$153 thousand

US Systems Research and Application Corporation (now part of CSRA)

$85 thousand

NETE Solutions

$8 thousand

Virginia industry in global health R&D

Celgene

Location(s): Arlington

CSRA

Location(s): Falls Church

Cupron

Location(s): Richmond

Jericho Sciences

Location(s): Fairfax Station

Luna Innovations

Location(s): Roanoke

Merck & Co

Location(s): Elton

Northrop Grumman

Location(s): Falls Church, Herndon

Parabon NanoLabs

Location(s): Reston

Thermal Gradient

Location(s): Richmond

Virongy

Location(s): Manassas

Virginia's top areas of global health R&D by USG funding

42.8%

HIV/AIDS

25.3%

Malaria

3.8%

Tuberculosis

9.9%

Diarrheal diseases

8.9%

Ebola/viral hemorrhagic fevers

4.5%

Neglected tropical diseases

Buruli ulcer

Dengue

Helminths

Kinetoplastids

Leprosy

4.8%

Other

Bacterial pneumonia & meningitis

Salmonella infections

Global health R&D at work in Virginia

Many drugs used to treat HIV/AIDS have life-threatening side effects. One new, highly effective drug doesn’t, but it’s extremely expensive to produce. Virginia Commonwealth University is aiming to make it cheaper. Drugs with fewer side effects are important for long-term care of HIV/AIDS patients, who must take the drugs for life. The university has a proven track record for reinventing how drugs are made, resulting in cost-effective products that save lives.

Footnotes

Methodology
USG global health R&D investment to state research institutions/Top USG-funded global health R&D institutions: Authors' analysis of USG investment data from the G-FINDER survey, including funding for R&D for neglected diseases from 2007–2015 and for Ebola and select viral hemorrhagic fevers from 2014–2015. Reflects USG funding received by entities in state including academic and research institutions, product development partnerships, other nonprofits, select corporations, and government research institutions, as well as self-funding or other federal agency transfers received by federal agencies located in state; but excludes pharmaceutical industry data which is aggregated and anonymized in the survey for confidentiality purposes. See methodology for additional details.
Jobs created: Based on previous analysis of the economic impact of National Institutes of Health R&D funding and author's analysis described above. See methodology for additional details.
Case study photo: PATH/Minzayar